Is Big Pharma Ignoring Small Biotech?
<p>Recent news might have you believe Big Pharma is turning its back on innovation hubs like small-cap biotech companies. Headlines scream about “dying deals” and a “broken acquisition market,” depicting a pharma giant spurning the next blockbuster cure. While sales potential undoubtedly influences biotech companies’ acquisition, it’s not the only criterion.</p>
<p>Here’s why the “Big Pharma vs. Small Biotech” narrative might be missing the mark:</p>
<p><a href="https://richardameyer.medium.com/is-big-pharma-ignoring-small-biotech-721e102d84de"><strong>Website</strong></a></p>